These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 1858560)

  • 1. apoB-containing lipoprotein particles as risk factors for coronary artery disease.
    Alaupovic P; Blackenhorn DH; Knight-Gibson C; Tavella M; Bard JM; Shafer D; Lee ET; Brasuell J
    Adv Exp Med Biol; 1991; 285():299-309. PubMed ID: 1858560
    [No Abstract]   [Full Text] [Related]  

  • 2. Quantitative and qualitative derangement of apolipoprotein B-containing lipoproteins as a risk factor for diabetic macroangiopathy in nonobese NIDDM subjects.
    Harano Y; Kageyama A; Nakao Y; Hara Y; Suzuki M; Sato A; Ikebuchi M; Shinozaki K; Tsushima M
    Diabetes; 1996 Jul; 45 Suppl 3():S31-4. PubMed ID: 8674886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relation of arteriographically defined coronary artery disease to serum lipoprotein particles mapped with monoclonal antibodies.
    Fiévet C; Nuttens MC; Ducimetière P; Fruchart JC; Bertrand M; Salomez JL
    Circulation; 1991 Jul; 84(1):153-9. PubMed ID: 2060091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoproteins, apolipoproteins and coronary artery disease.
    Fruchart JC; Parra H; Cachera C; Clavey V; Bertrand M
    Ric Clin Lab; 1982; 12(1):101-6. PubMed ID: 6806881
    [No Abstract]   [Full Text] [Related]  

  • 5. Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study.
    Tani S; Yagi T; Atsumi W; Kawauchi K; Matsuo R; Hirayama A
    Cardiovasc Diabetol; 2017 Oct; 16(1):123. PubMed ID: 28969633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atherogenic lipoprotein profile in families with and without history of early myocardial infarction.
    Dobiásová M; Raslová K; Rauchová H; Vohnout B; Ptácková K; Frohlich J
    Physiol Res; 2001; 50(1):1-8. PubMed ID: 11300220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolism of apolipoprotein B-48-containing triglyceride-rich lipoproteins in noninsulin-dependent diabetes mellitus.
    Nakai T; Takai H; Tamai T; Oida K; Maeda H; Takahashi S; Miyabo S
    Prog Lipid Res; 1991; 30(2-3):281-94. PubMed ID: 1823947
    [No Abstract]   [Full Text] [Related]  

  • 8. Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in type II diabetes.
    Gervaise N; Garrigue MA; Lasfargues G; Lecomte P
    Diabetologia; 2000 Jun; 43(6):703-8. PubMed ID: 10907114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk.
    Walldius G; Jungner I; Aastveit AH; Holme I; Furberg CD; Sniderman AD
    Clin Chem Lab Med; 2004; 42(12):1355-63. PubMed ID: 15576296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of age on the association of non-high-density-lipoprotein cholesterol and apolipoprotein B with cardiovascular mortality in a Mediterranean population with type 2 diabetes: the Casale Monferrato study.
    Bruno G; Merletti F; Biggeri A; Bargero G; Prina-Cerai S; Pagano G; Cavallo-Perin P
    Diabetologia; 2006 May; 49(5):937-44. PubMed ID: 16525840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes.
    Berneis K; Jeanneret C; Muser J; Felix B; Miserez AR
    Metabolism; 2005 Feb; 54(2):227-34. PubMed ID: 15690318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triglyceride-rich lipoproteins and the progression of coronary artery disease.
    Hodis HN; Mack WJ
    Curr Opin Lipidol; 1995 Aug; 6(4):209-14. PubMed ID: 7670749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100.
    Véniant MM; Sullivan MA; Kim SK; Ambroziak P; Chu A; Wilson MD; Hellerstein MK; Rudel LL; Walzem RL; Young SG
    J Clin Invest; 2000 Dec; 106(12):1501-10. PubMed ID: 11120757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events.
    Stojakovic T; de Campo A; Scharnagl H; Sourij H; Schmölzer I; Wascher TC; März W
    Eur J Clin Invest; 2010 Mar; 40(3):187-94. PubMed ID: 20067513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apoprotein B: a discriminator of coronary heart disease.
    Sung ML; Tsai TY; Liang YH; Wang CS; Lin CH; Hsieh CC; Lue SA
    Taiwan Yi Xue Hui Za Zhi; 1986 Apr; 85(4):368-75. PubMed ID: 3462320
    [No Abstract]   [Full Text] [Related]  

  • 16. Genetic contributions to quantitative lipoprotein traits associated with coronary artery disease: analysis of a large pedigree from the Bogalusa Heart Study.
    Heiba IM; DeMeester CA; Xia YR; Diep A; George VT; Amos CI; Srinivasan SR; Berenson GS; Elston RC; Lusis AJ
    Am J Med Genet; 1993 Nov; 47(6):875-83. PubMed ID: 8279486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study.
    Duvillard L; Pont F; Florentin E; Galland-Jos C; Gambert P; Vergès B
    Eur J Clin Invest; 2000 Aug; 30(8):685-94. PubMed ID: 10964160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Characteristics of lipid composition of blood serum lipoproteins in insulin resistance].
    Sokolik VV; Chursina VS; Rodenko OS; Bozhko GKh
    Ukr Biokhim Zh (1999); 2007; 79(2):62-9. PubMed ID: 18030752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atherogenicity of triglyceride-rich lipoproteins.
    Krauss RM
    Am J Cardiol; 1998 Feb; 81(4A):13B-17B. PubMed ID: 9526808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The use of apolipoprotein B in clinical practice to determine the risk for atherosclerosis].
    Cabezas Castro M; Liem A
    Ned Tijdschr Geneeskd; 2003 Jul; 147(30):1445-8. PubMed ID: 12908345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.